MICHAEL X WANG, MD
Medical Practice in Columbia, MO
License number
Missouri 2004035778
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
License number
Missouri 2004035778
Category
Medical Practice
Type
Hematology
Address
Address
One Hospital Dr, Columbia, MO 65212
Phone
(573) 882-1276
(573) 882-2259
(573) 882-2259
Personal information
See more information about MICHAEL X WANG at radaris.comName
Address
Phone
4606 Connery Ct, Columbia, MO 65203
1108 117Th St, Kansas City, MO 64131
Professional information
See more information about MICHAEL X WANG at trustoria.com
Assistant Professor/Clinical Pathologist At University Of Missouri-Columbia
Assistant Professor/Clinical Pathologist At University Of Missouri-Columbia
Position:
Assistant Professor/Clinical Pathologist at University of Missouri-Columbia
Location:
Columbia, Missouri Area
Industry:
Research
Work:
University of Missouri-Columbia
-
Assistant Professor/Clinical Pathologist
Dr. Michael X Wang, Columbia MO - MD (Doctor of Medicine)
Dr. Michael X Wang, Columbia MO - MD (Doctor of Medicine)
Specialties:
Hematology, Hematopathology, Molecular Genetic Pathology
Address:
1 Hospital Dr, Columbia 65201
(573) 882-1276 (Phone), (573) 884-4611 (Fax)
(573) 882-1276 (Phone), (573) 884-4611 (Fax)
Languages:
English
Hospitals:
1 Hospital Dr, Columbia 65201
University of Missouri Hospital and Clinics
1 Hospital Dr, Columbia 65212
University of Missouri Hospital and Clinics
1 Hospital Dr, Columbia 65212
Education:
Medical School
University Of California, Irvine, College Of Medicine
Graduated: 2000
University Of California, Irvine, College Of Medicine
Graduated: 2000
Method For Detecting Dna Methylation In Cancer Cells
Method For Detecting Dna Methylation In Cancer Cells
US Patent:
2010024, Sep 30, 2010
Filed:
Mar 27, 2009
Appl. No.:
12/383790
Inventors:
Michael Xia Wang - Columbia MO, US
Huidong Shi - Martinez GA, US
Srilatha Nalluri - Augusta GA, US
Huidong Shi - Martinez GA, US
Srilatha Nalluri - Augusta GA, US
Assignee:
The Curators of the University of Missouri - Columbia MO
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention provides a detecting method of detecting malignant cells in a patient's specimen or a biological sample. Specifically, the inventive method includes the steps of extracting a genomic DNA, digesting said genomic DNA with one or multiple methylation sensitive restriction enzymes, and amplifying by PCR with one or multiple selected primers. The PCR can be performed in a conventional or a real-time platform. The inventive method can detect leukemia cells in 90% ALL patients at a sensitivity of up to 10. The inventive method also provides broad clinical applications in cancer (including hematopoietic and solid tumors) screening and risk assessment, early detection and diagnosis confirmation, and therapeutic monitoring, minimal residual disease detection and prognostic prediction.
Methods For Detecting Rare Circulating Cancer Cells Using Dna Methylation Biomarkers
Methods For Detecting Rare Circulating Cancer Cells Using Dna Methylation Biomarkers
US Patent:
2012020, Aug 9, 2012
Filed:
Jan 27, 2012
Appl. No.:
13/360649
Inventors:
Michael Xia WANG - Columbia MO, US
Charles W. Caldwell - Columbia MO, US
Kristen H. Taylor - Columbia MO, US
Srilatha Nalluri - Augusta GA, US
Dali Zheng - St. Louis MO, US
Charles W. Caldwell - Columbia MO, US
Kristen H. Taylor - Columbia MO, US
Srilatha Nalluri - Augusta GA, US
Dali Zheng - St. Louis MO, US
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
Provided are new and improved methods for detecting circulating tumor cells and tumor cell DNA in patient blood or other biofluid samples. Particular aspects comprise three steps: DNA extraction from patient samples, DNA digestion with multiple selected methylation-sensitive enzymes, and target amplification by a conventional or a real-time PCR with specific probe and/or primers. Also provided are a total of 40 tumor-specific DNA methylation loci as biomarkers having substantial utility and specificity in major types of human malignancies including hematopoietic and solid tumors.